Literature DB >> 19204414

Pharmacogenomics and public health.

D Veenstra1, W Burke.   

Abstract

Mesh：

Year:  2009        PMID： 19204414      PMCID： PMC2836943          DOI： 10.1159/000189624

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN： 1662-4246            Impact factor:   2.000


× No keyword cloud information.
  14 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Pharmacogenomics, evidence, and the role of payers.

Authors:  P A Deverka
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

3.  Pharmacogenetics in Europe: barriers and opportunities.

Authors:  D Gurwitz; E Zika; M M Hopkins; S Gaisser; D Ibarreta
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

4.  Researchers' perceptions of the ethical implications of pharmacogenomics research with children.

Authors:  D Avard; T Silverstein; G Sillon; Y Joly
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

5.  Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.

Authors:  David L Veenstra; Julie Harris; Ronald L Gibson; Margaret Rosenfeld; Wylie Burke; Carolyn Watts
Journal:  Genet Med       Date:  2007-10       Impact factor: 8.822

Review 6.  Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

Authors:  M P Goetz; A Kamal; M M Ames
Journal:  Clin Pharmacol Ther       Date:  2007-09-19       Impact factor: 6.875

7.  Assessing patient readiness for the clinical adoption of personalized medicine.

Authors:  A M Issa; W Tufail; J Hutchinson; J Tenorio; M Poonam Baliga
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

8.  The potential of a placebo/nocebo effect in pharmacogenetics.

Authors:  S B Haga; L R Warner; J O'Daniel
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

Review 9.  Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.

Authors:  L Wang; R Weinshilboum
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

Review 10.  Warfarin pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705
View more
  3 in total

1.  End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.

Authors:  Vural Ozdemir; Erik Fisher; Edward S Dove; Hilary Burton; Galen E B Wright; Mario Masellis; Louise Warnich
Journal:  Curr Pharmacogenomics Person Med       Date:  2012-01-01

2.  Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.

Authors:  Susan R Snyder; Jing Hao; Larisa H Cavallari; Zhi Geng; Amanda Elsey; Julie A Johnson; Zahurin Mohamed; Nathorn Chaiyakunapruk; Huey Yi Chong; Maznah Dahlui; Fatiha H Shabaruddin; George P Patrinos; Christina Mitropoulou; Marc S Williams
Journal:  Public Health Genomics       Date:  2019-06-12       Impact factor: 2.000

Review 3.  Is individualized medicine more cost-effective? A systematic review.

Authors:  Maximilian H M Hatz; Katharina Schremser; Wolf H Rogowski
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.